Bridgewater Bancshares, Inc. – Consensus Indicates Potential 19.0% Upside

DirectorsTalk Interviews

Bridgewater Bancshares, Inc. found using ticker (BWB) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 21 and 19.5 and has a mean target at 20.25. With the stocks previous close at 17.02 this indicates there is a potential upside of 19.0%. The 50 day moving average now sits at 17.1 and the 200 day moving average is 16.92. The company has a market capitalisation of $476m. Company Website: https://www.bridgewaterbankmn.com

The potential market cap would be $566m based on the market concensus.

Bridgewater Bancshares, Inc. operates as the bank holding company for Bridgewater Bank that provides banking products and services to commercial real estate investors, small business entrepreneurs, and high net worth individuals in the United States. The company offers savings and money market accounts, demand deposits, time and brokered deposits, and interest and noninterest bearing transaction, as well as certificates of deposit. It also provides commercial loans to sole proprietorships, partnerships, corporations, and other business enterprises to finance accounts receivable or inventory, capital assets, or other business-related purposes; paycheck protection program loans; construction and land development loans; 1-4 family mortgage loans; multifamily lending products; owner and non-owner occupied commercial real estate loans; and consumer and other loans. In addition, the company online, mobile, and direct banking services. It operates through seven full-service offices located in Bloomington, Greenwood, Minneapolis, St. Louis Park, Orono, and St. Paul, Minnesota. The company was incorporated in 2005 and is headquartered in Saint Louis Park, Minnesota.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search